{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:55:02Z","timestamp":1790762102528,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Hospital Organization","award":["H26-NHO (AIDS)-03"],"award-info":[{"award-number":["H26-NHO (AIDS)-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-018-3643-2","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T07:49:14Z","timestamp":1546674554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical characteristics of HIV-1-infected patients with high levels of plasma interferon-\u03b3: a multicenter observational study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3838-0961","authenticated-orcid":false,"given":"Dai","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Uehira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erina","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Takahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimikazu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"key":"3643_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/08820139709022691","volume":"26","author":"K Alonso","year":"1997","unstructured":"Alonso K, Pontiggia P, Medenica R, Rizzo S. Cytokine patterns in adults with AIDS. Immunol Investig. 1997;26:341\u201350.","journal-title":"Immunol Investig"},{"key":"3643_CR2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/CDLI.5.6.755-761.1998","volume":"5","author":"N Aziz","year":"1998","unstructured":"Aziz N, Nishanian P, Fahey JL. Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Clin Diagn Lab Immunol. 1998;5:755\u201361.","journal-title":"Clin Diagn Lab Immunol"},{"key":"3643_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1086\/605890","volume":"200","author":"MA French","year":"2009","unstructured":"French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200:1212\u20135.","journal-title":"J Infect Dis"},{"key":"3643_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/infdis\/jiv004","volume":"212","author":"CO Hileman","year":"2015","unstructured":"Hileman CO, Kinley B, Scharen-Guivel V, Melbourne K, Szwarcberg J, Robinson J, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis. 2015;212:345\u201354.","journal-title":"J Infect Dis"},{"key":"3643_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","volume":"29","author":"NI Wada","year":"2015","unstructured":"Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29:463\u201371.","journal-title":"AIDS"},{"key":"3643_CR6","doi-asserted-by":"publisher","first-page":"e0167091","DOI":"10.1371\/journal.pone.0167091","volume":"11","author":"S Swaminathan","year":"2016","unstructured":"Swaminathan S, Qiu J, Rupert AW, Hu Z, Higgins J, Dewar RL, et al. Interleukin-15 (IL-15) strongly correlates with increasing HIV-1 viremia and markers of inflammation. PLoS One. 2016;11:e0167091.","journal-title":"PLoS One"},{"key":"3643_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1089\/vim.2010.0065","volume":"23","author":"D Watanabe","year":"2010","unstructured":"Watanabe D, Uehira T, Yonemoto H, Bando H, Ogawa Y, Yajima K, et al. Sustained high levels of serum interferon-gamma during HIV-1 infection: a specific trend different from other cytokines. Viral Immunol. 2010;23:619\u201325.","journal-title":"Viral Immunol"},{"key":"3643_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","volume":"4","author":"SR Roff","year":"2014","unstructured":"Roff SR, Noon-Song EN, Yamamoto JK. The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis. Front Immunol. 2014;4:498.","journal-title":"Front Immunol"},{"key":"3643_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"AR Tenorio","year":"2014","unstructured":"Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248\u201359.","journal-title":"J Infect Dis"},{"key":"3643_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/infdis\/jiv123","volume":"212","author":"AH Borges","year":"2015","unstructured":"Borges AH, O'Connor JL, Phillips AN, Ronsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis. 2015;212:585\u201395.","journal-title":"J Infect Dis"},{"key":"3643_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/cid\/ciw409","volume":"63","author":"NI Wada","year":"2016","unstructured":"Wada NI, Bream JH, Martinez-Maza O, Macatangay B, Galvin SR, Margolick JB, et al. Inflammatory biomarkers and mortality risk among HIV-suppressed men: a multisite prospective cohort study. Clin Infect Dis. 2016;63:984\u201390.","journal-title":"Clin Infect Dis"},{"key":"3643_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41598-017-18647-6","volume":"8","author":"M Shoji","year":"2018","unstructured":"Shoji M, Takemoto M, Kobayashi K, Shoji T, Mori S, Sagara JI, et al. Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis. Sci Rep. 2018;8:245.","journal-title":"Sci Rep"},{"key":"3643_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10157-017-1427-4","volume":"22","author":"H Kato","year":"2018","unstructured":"Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, et al. Rationale and design of oBservational clinical research in chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia to erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN trial). Clin Exp Nephrol. 2018;22:78\u201384.","journal-title":"Clin Exp Nephrol"},{"key":"3643_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2147\/TCRM.S80647","volume":"11","author":"D Asaoka","year":"2015","unstructured":"Asaoka D, Nagahara A, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, et al. Risk factors for osteoporosis in Japan: is it associated with helicobacter pylori? Ther Clin Risk Manag. 2015;11:381\u201391.","journal-title":"Ther Clin Risk Manag"},{"key":"3643_CR15","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.micinf.2006.09.003","volume":"8","author":"I Koga","year":"2006","unstructured":"Koga I, Odawara T, Matsuda M, Sugiura W, Goto M, Nakamura T, et al. Analysis of HIV-1 sequences before and after co-infecting syphilis. Microbes Infect. 2006;8:2872\u20139.","journal-title":"Microbes Infect"},{"key":"3643_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/QAD.0000000000000771","volume":"29","author":"H Mori","year":"2015","unstructured":"Mori H, Kojima Y, Kawahata T, Matsuura M, Uno K, Konishi M, et al. A cluster of rapid disease progressors upon primary HIV-1 infection shared a novel variant with mutations in the p6gag\/pol and pol\/vif genes. AIDS. 2015;29:1717\u20139.","journal-title":"AIDS"},{"key":"3643_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jir134","volume":"203","author":"DR Boulware","year":"2011","unstructured":"Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203:1637\u201346.","journal-title":"J Infect Dis"},{"key":"3643_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1468-1293.2003.00156.x","volume":"4","author":"E Florence","year":"2003","unstructured":"Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4:255\u201362.","journal-title":"HIV Med."},{"key":"3643_CR19","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1097\/00002030-200411050-00018","volume":"18","author":"F Dronda","year":"2004","unstructured":"Dronda F, Zamora J, Moreno S, Moreno A, Casado JL, Muriel A, et al. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS. 2004;18:2210\u20132.","journal-title":"AIDS"},{"key":"3643_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/157016208783885038","volume":"6","author":"F Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez F, Padilla S, Masi\u00e1 M, Iribarren JA, Moreno S, Viciana P, et al. Patients\u2019 characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res. 2008;6:100\u20137.","journal-title":"Curr HIV Res"},{"key":"3643_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1742-6405-5-23","volume":"5","author":"D Nakanjako","year":"2008","unstructured":"Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther. 2008;5:23.","journal-title":"AIDS Res Ther"},{"key":"3643_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/QAD.0b013e328337b957","volume":"24","author":"M Massanella","year":"2010","unstructured":"Massanella M, Negredo E, Perez-Alvarez N, Puig J, Ruiz-Hernandez R, Bofill M, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010;24:959\u201368.","journal-title":"AIDS"},{"key":"3643_CR23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1086\/651689","volume":"50","author":"E Negredo","year":"2010","unstructured":"Negredo E, Massanella M, Puig J, Perez-Alvarez N, Gallego-Escuredo JM, Villarroya J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010;50:1300\u20138.","journal-title":"Clin Infect Dis"},{"key":"3643_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09540121003617372","volume":"22","author":"T Wilkin","year":"2010","unstructured":"Wilkin T. What causes poor CD4-cell recovery in the setting of suppressive ART? J Watch AIDS Clin Care. 2010;22:51.","journal-title":"J Watch AIDS Clin Care"},{"key":"3643_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/1471-2334-10-318","volume":"10","author":"FN Engsig","year":"2010","unstructured":"Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Roge B, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis. 2010;10:318.","journal-title":"BMC Infect Dis"},{"key":"3643_CR26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cid\/ciu038","volume":"58","author":"FN Engsig","year":"2014","unstructured":"Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58:1312\u201321.","journal-title":"Clin Infect Dis"},{"key":"3643_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cei.12278","volume":"176","author":"J Saison","year":"2014","unstructured":"Saison J, Ferry T, Demaret J, Maucort Boulch D, Venet F, Perpoint T, et al. Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol. 2014;176:401\u20139.","journal-title":"Clin Exp Immunol"},{"key":"3643_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1089\/apc.2015.0040","volume":"29","author":"JL Marcus","year":"2015","unstructured":"Marcus JL, Leyden WA, Chao CR, Xu L, Quesenberry CP Jr, Tien PC, et al. Differences in response to antiretroviral therapy by sex and hepatitis C infection status. AIDS Patient Care STDs. 2015;29:370\u20138.","journal-title":"AIDS Patient Care STDs"},{"key":"3643_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5582\/bst.2015.01107","volume":"9","author":"F Zhang","year":"2015","unstructured":"Zhang F, Sun M, Sun J, Guan L, Wang J, Lu H. The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China. Biosci Trends. 2015;9:335\u201341.","journal-title":"Biosci Trends"},{"key":"3643_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/eci.12539","volume":"45","author":"M Guzman-Fulgencio","year":"2015","unstructured":"Guzman-Fulgencio M, Berenguer J, Jimenez-Sousa MA, Micheloud D, Garc\u00eda-\u00c1lvarez M, Bell\u00f3n JM, et al. IL7RA polymorphisms predict the CD4+ recovery in HIV patients on cART. Eur J Clin Investig. 2015;45:1192\u20139.","journal-title":"Eur J Clin Investig"},{"key":"3643_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cyto.2015.11.009","volume":"77","author":"S Singh","year":"2016","unstructured":"Singh S, Sharma A, Arora SK. Combination of low producer AA-genotypes in IFN-gamma and IL-10 genes makes a high risk genetic variant for HIV disease progression. Cytokine. 2016;77:135\u201344.","journal-title":"Cytokine"},{"key":"3643_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/hiv.12354","volume":"17","author":"J Collazos","year":"2016","unstructured":"Collazos J, Valle-Garay E, Carton JA, Montes AH, Suarez-Zarracina T, De la Fuente B, et al. Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy. HIV Med. 2016;17:532\u201341.","journal-title":"HIV Med"},{"key":"3643_CR33","doi-asserted-by":"publisher","first-page":"ofw140","DOI":"10.1093\/ofid\/ofw140","volume":"3","author":"M Anderson","year":"2016","unstructured":"Anderson M, Gaseitsiwe S, Moyo S, Thami KP, Mohammed T, Setlhare D, et al. Slow CD4+ T-cell recovery in human immunodeficiency virus\/hepatitis B virus-coinfected patients initiating truvada-based combination antiretroviral therapy in Botswana. Open Forum Infect Dis. 2016;3:ofw140.","journal-title":"Open Forum Infect Dis."},{"key":"3643_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/QAI.0000000000001080","volume":"73","author":"B Stiksrud","year":"2016","unstructured":"Stiksrud B, Lorvik KB, Kvale D, Mollnes TE, Ueland PM, Tr\u00f8seid M, et al. Plasma IP-10 is increased in immunological nonresponders and associated with activated regulatory T cells and persisting low CD4 counts. J Acquir Immune Defic Syndr. 2016;73:138\u201348.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3643_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2017.03.015","volume":"142","author":"I Rosado-S\u00e1nchez","year":"2017","unstructured":"Rosado-S\u00e1nchez I, Jarr\u00edn I, Pozo-Balado MM, de Pablo-Bernal RS, Herrero-Fern\u00e1ndez I, Alvarez-R\u00edos AI, et al. Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery. Antivir Res. 2017;142:76\u201382.","journal-title":"Antivir Res"},{"key":"3643_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13104-017-2521-0","volume":"10","author":"DW Gunda","year":"2017","unstructured":"Gunda DW, Kilonzo SB, Kamugisha E, Rauya EZ, Mpondo BC. Prevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment Centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study. BMC Res Notes. 2017;10:197.","journal-title":"BMC Res Notes"},{"key":"3643_CR37","doi-asserted-by":"crossref","unstructured":"Darraj M, Shafer LA, Chan S, Kasper K, Keynan Y. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression. J Infect Public Health. 2018;11:265\u20139.","DOI":"10.1016\/j.jiph.2017.08.001"},{"key":"3643_CR38","doi-asserted-by":"publisher","first-page":"ofw025","DOI":"10.1093\/ofid\/ofw025","volume":"3","author":"PJ Norris","year":"2016","unstructured":"Norris PJ, Zhang J, Worlock A, Nair SV, Anastos K, Minkoff HL, et al. Systemic cytokine levels do not predict CD4+ T-cell recovery after suppressive combination antiretroviral therapy in chronic human immunodeficiency virus infection. Open Forum Infect Dis. 2016;3:ofw025.","journal-title":"Open Forum Infect Dis"},{"key":"3643_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cyto.2016.12.010","volume":"91","author":"Q Richert","year":"2017","unstructured":"Richert Q, Trajtman A, Arroyave L, Toews J, Becker M, Kasper K, et al. Systemic inflammation before and after antiretroviral therapy initiation as a predictor of immune response among HIV-infected individuals in Manitoba. Cytokine. 2017;91:74\u201381.","journal-title":"Cytokine"},{"key":"3643_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.gene.6364189","volume":"6","author":"HW Tso","year":"2005","unstructured":"Tso HW, Ip WK, Chong WP, Tam CM, Chiang AK, Lau YL. Association of interferon gamma and interleukin 10 genes with tuberculosis in Hong Kong Chinese. Genes Immun. 2005;6:358\u201363.","journal-title":"Genes Immun"},{"key":"3643_CR41","first-page":"110","volume":"56","author":"RC Sobti","year":"2010","unstructured":"Sobti RC, Salih AM, Nega B, Seyed AH, Rupinder K, Vijesh K, et al. Insights into the role of IL-12B and IFN-gamma cytokine gene polymorphisms in HIV-1\/AIDS infection. Folia Biol (Praha). 2010;56:110\u20135.","journal-title":"Folia Biol (Praha)"},{"key":"3643_CR42","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.humimm.2016.08.001","volume":"77","author":"VR Gutlapalli","year":"2016","unstructured":"Gutlapalli VR, Sykam A, Tenali SP, Suneetha S, Suneetha LM. High levels of plasma interferon gamma and +874T\/a gene polymorphism is associated with HIV-TB co-infection. Hum Immunol. 2016;77:1264\u201370.","journal-title":"Hum Immunol"},{"key":"3643_CR43","unstructured":"Freitas FB, Lima SS, Feitosa RN, Azevedo VN, Ishak Mde O, Ishak R, et al. Polymorphisms in the IFN\u03b3, IL-10, and TGF\u03b2 genes may be associated with HIV-1 infection. Dis Markers 2015;2015:248571."},{"key":"3643_CR44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3109\/08820139.2016.1157603","volume":"45","author":"PG Carvalho de","year":"2016","unstructured":"de Carvalho PG, de Oliveira Rodrigues R, Ribeiro da Silva SF, Ribeiro IF, de Miranda Lucena HB, Martins LR, et al. CD38+CD8+ and CD38+CD4+ T cells and IFN gamma (+874) polymorphism are associated with a poor Virological outcome. Immunol Investig. 2016;45:312\u201327.","journal-title":"Immunol Investig"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3643-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T19:05:13Z","timestamp":1578164713000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3643-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3643"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3643-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"5 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed after an ethics approval H26-NHO (AIDS)-03 had been received from the Central Institutional Review Board Committee of the National Hospital Organization of Japan. The procedures were carried out in accordance with relevant guidelines and regulations. All samples were collected after acquiring written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"11"}}